<DOC>
	<DOCNO>NCT02069041</DOCNO>
	<brief_summary>The main purpose study determine advise dose ramucirumab safe take chemotherapy treatment participant advance liver tumor .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Participants With Advanced Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histological cytological diagnosis hepatocellular carcinoma ( HCC ) image finding consistent HCC participant liver cirrhosis alphafetoprotein &gt; 200 nanogram per milliliter At least 1 measurable nonmeasurable lesion ChildPugh A Barcelona Clinic Liver Cancer ( BCLC ) stage C BCLC stage B amenable locoregional therapy refractory locoregional therapy Eastern Cooperative Oncology Group Performance Status 0 1 Have receive previous systemic therapy advance HCC Have resolution Grade ≤1 clinically significant toxic effect prior locoregional therapy Adequate organ function include : Absolute neutrophil coun t≥1.5×109/liter ( L ) , hemoglobin ≥9 gram/deciliter , platelet ≥90×109/L ; Total bilirubin level ≤1.5 upper limit normal range ( ULN ) , aspartate transaminase alanine transaminase ≤5 ULN , albumin &gt; 28 gram/L ; Serum creatinine level ≤1.5 ULN ; calculate serum creatinine clearance ≥50 milliliter/minute ; International Normalized Ratio≤1.5 partial thromboplastin time ≤5 second ULN The urinary protein ≤ 1+ . If ≥ 2+ proteinuria , 24hour urine protein &lt; 1000 milligram An estimate life expectancy least 12 week Received investigational therapy nonapproved drug within 28 day prior enrollment Undergone major surgery within 28 day prior enrollment , undergone central venous access device placement within 7 day prior enrollment Undergone hepatic locoregional therapy within 28 day prior enrollment Undergone radiation nonhepatic site within 14 day prior enrollment Prior liver transplant Fibrolamellar carcinoma cholangiocellular carcinoma Received transfusion , blood component preparation , erythropoietin , albumin preparation , granulocytecolony stimulating factor within 14 day prior enrollment Receiving therapeutic anticoagulation warfarin , lowmolecular weight heparin , similar agent Receiving ongoing therapy nonsteroidal antiinflammatory agent antiplatelet agent . Known human immunodeficiency virus infection acquire immunodeficiency syndromerelated illness Active uncontrolled clinically serious infection Uncontrolled thrombotic hemorrhagic disorder Serious nonhealing wound , ulcer , bone fracture within 28 day prior enrollment History gastrointestinal perforation obstruction History current hepatic encephalopathy current clinically meaningful ascites Known allergy monoclonal antibody , fluorouracil , oxaliplatin excipients Interstitial pneumonia interstitial fibrosis lung Central nervous system metastases carcinomatous meningitis Known history dihydropyrimidine dehydrogenase deficiency Symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia Experienced arterial thromboembolic event Uncontrolled arterial hypertension Grade 34 venous thromboembolic event occur within 3 month prior enrollment Experienced grade 34 gastrointestinal bleeding variceal bleed episode 3 month prior enrollment require transfusion , endoscopic operative intervention Esophageal gastric varix require immediate intervention represent high bleeding risk Preexisting grade ≥ 2 motor sensory neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>